A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia

Sponsor
Lynk Pharmaceuticals Co., Ltd (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04896112
Collaborator
(none)
93
Enrollment
2
Locations
9
Arms
32.5
Anticipated Duration (Months)
46.5
Patients Per Site
1.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid leukemia (AML).

Detailed Description

This is a Phase I, open-label, dose-finding study of the triple kinase inhibitor LNK01002 in patients with myelofibrosis (MF). The study consists of two periods: the dose escalation, main period and a dose expansion period. In the dose escalation period, successive cohorts of patients with MF will be enrolled to establish the maximum tolerated dose. In the dose expansion period (dose-confirmation phase), three cohorts of patients will be enrolled: AML patients with confirmed FLT3-ITD mutations, AML patients without FLT3-ITD mutations, and patients with primary MF or PV/ET-MF.

The safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of LNK01002 in patients with myelofibrosis/AML will be evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
93 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
Actual Study Start Date :
Apr 8, 2021
Anticipated Primary Completion Date :
Oct 23, 2023
Anticipated Study Completion Date :
Dec 23, 2023

Arms and Interventions

ArmIntervention/Treatment
Experimental: Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg

Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles

Drug: LNK01002
LNK01002 will be administrated orally.
Other Names:
  • LNK-1000318
  • Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg

    LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg

    LNK01002 45 mg BID, followed by a 3-day observation period then 45 mg BID in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg

    LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg

    LNK01002 80 mg BID, followed by a 3-day observation period then 80 mg BID in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg

    LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Acute Myeloid Leukemia With Mutant FLT3

    LNK01002 at the RP2D dose in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3

    LNK01002 at the RP2D dose in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Experimental: Patients with Primary or Secondary Myelofibrosis

    LNK01002 at the RP2D dose in 28-day treatment cycles

    Drug: LNK01002
    LNK01002 will be administrated orally.
    Other Names:
  • LNK-1000318
  • Outcome Measures

    Primary Outcome Measures

    1. Assessing the safety and tolerability of LNK01002 in patients with myelofibrosis [31 days]

      Assessed by monitoring the frequency, duration and severity of adverse events and serious adverse events.

    2. Assessing maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of LNK01002 in patients with myelofibrosis [31 days]

      Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) will be assessed based on the safety profile by the SRC

    3. Assessing the preliminary antitumor activity of LNK01002 [24 Weeks]

      The preliminary antitumor activity will be analyzed in patients with different types of malignant myeloid hematologic neoplasms by response rate using bone marrow and hematologic analyses (MF/AML) or by the MF Symptom Assessment Scale and spleen volume by MRI (MF).

    Secondary Outcome Measures

    1. Measurement of pharmacokinetic (PK) parameter, AUC, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    2. Measurement of pharmacokinetic (PK) parameter, Cmax, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    3. Measurement of pharmacokinetic (PK) parameter, Tmax, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    4. Measurement of pharmacokinetic (PK) parameter, CL/F, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    5. Measurement of pharmacokinetic (PK) parameter, T1/2, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    6. Measurement of pharmacokinetic (PK) parameter, Vz/F, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    7. Measurement of pharmacokinetic (PK) parameter, MRT, in MF, PV-MF or ET-MF patients [Day 1, Day 2, and Day 15]

      Measurement will be using extensive PK sampling

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age: 18 years old or older, male or female.

    2. Patients must have histologically or cytologically confirmed tumors of the following types.

    3. Dose Escalation Phase: Patients with PMF, PV/ET-MF

    4. Intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis which failed standard treatment.

    5. Symptomatic splenomegaly

    6. Not undergone splenectomy or splenic radiation therapy within 6 months prior to screening.

    7. Dose expansion phase: Patients with PMF, PV/ET-MF who relapsed or are intolerant to standard treatment, and relapsed/refractory AML

    8. Platelet count ≥ 100 × 10e9/L within 14 days before study drug administration

    9. Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L within 14 days before study drug administration

    10. Women of childbearing potential negative pregnancy test at screening. Female patients of childbearing potential, or male patients and their partners should agree to effective contraception from signing ICF until 6 months after the last dose of study drug.

    Exclusion Criteria:

    Patients who meet any of the following exclusion criteria will be excluded from the clinical study:

    1. Allergic to any component of LNK01002.

    2. Serum total bilirubin greater than 1.5 times the upper limit of the normal (ULN) reference range, except patients diagnosed as Gilbert's disease

    3. ALT or AST higher than 3 times the ULN reference range without hepatic involvement by leukemia, which are excluded if higher than 5 times the ULN

    4. Glomerular filtration rate or estimated creatinine clearance < 50 mL/min according to the Cockcroft-Gault formula;

    5. Serum amylase or lipase levels higher than the ULN and considered clinically significant

    6. International normalized ratio (INR) or partial activated prothrombin time (aPTT) above 1.5 times the ULN reference range

    7. Known history of clinically significant liver disease, including viral or other hepatitis:

    1. Patients with hepatitis B or hepatitis C may be enrolled if they have a negative polymerase chain reaction (PCR)
    1. Known human immunodeficiency virus (HIV) infection;

    2. Clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery within 6 months before enrollment, congestive heart failure with New York Heart Association (NYHA) classification of III or above, left ventricular ejection fraction (LVEF) < 50%, or uncontrolled hypertension, cardiac arrhythmia;

    3. Patients with history or presence of clinically relevant non-malignant CNS disease requiring treatment

    4. Patients who have received systemic antineoplastic therapy or radiotherapy within 2 weeks prior to start of study treatment:

    5. Patients who have received hematopoietic stem cell transplantation (HSCT) within 60 days prior to the start of study treatment, or are receiving immunosuppressive therapy after HSCT at screening, or have graft-versus-host disease (GVHD) requiring drug control:

    6. Received anti-tumor Chinese herbal medicine treatment within 1 week before the start of study treatment;

    7. Received CYP3A substrates, CYP2B6 substrates, CYP2C substrates, OATP1B3 substrates, UGT1A1 inhibitors, or UGT1A3 inhibitors less than one week or 5 half-lives (whichever is longer) prior to the start of study treatment;

    8. Uncontrolled, active infections requiring intravenous antibiotic treatment;

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Revive Research InstituteFarmington HillsMichiganUnited States48334
    2Revive Research InstituteSterling HeightsMichiganUnited States48314

    Sponsors and Collaborators

    • Lynk Pharmaceuticals Co., Ltd

    Investigators

    • Study Director: Sherry Weigand, M.D., Ph.D., Lynk Pharmaceuticals Co., Ltd

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lynk Pharmaceuticals Co., Ltd
    ClinicalTrials.gov Identifier:
    NCT04896112
    Other Study ID Numbers:
    • LNK-1002-01
    • IND 153144
    First Posted:
    May 21, 2021
    Last Update Posted:
    Jun 9, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lynk Pharmaceuticals Co., Ltd
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 9, 2021